Cystitis Differential Diagnosis: A Comprehensive Guide for Clinicians

Introduction

Cystitis, commonly known as a bladder infection, is a frequent clinical entity, particularly in women. Characterized by lower urinary tract symptoms, it is broadly classified into uncomplicated and complicated forms. While often straightforward to diagnose and treat, especially in uncomplicated cases, accurate diagnosis is paramount to ensure appropriate management and avoid unnecessary antibiotic use. A crucial aspect of managing patients presenting with symptoms suggestive of cystitis is considering the Cystitis Differential Diagnosis. This article aims to provide a detailed overview of cystitis, focusing on its differential diagnosis to guide clinicians in effectively distinguishing it from other conditions presenting with similar symptoms. Understanding the nuances of differential diagnosis is essential for optimal patient care and to mitigate the risks associated with misdiagnosis and inappropriate treatment.

Etiology of Cystitis

Acute cystitis is predominantly caused by bacterial infections, with Escherichia coli being the most frequently identified pathogen in uncomplicated cases. Other bacterial culprits include Klebsiella, Proteus mirabilis, Staphylococcus saprophyticus, and Enterococcus species. In complicated cystitis, the range of potential pathogens expands to include organisms such as Enterobacter, Citrobacter, Serratia, Pseudomonas, and even fungi, often exhibiting higher rates of antimicrobial resistance.

The pathogenesis of cystitis typically involves the colonization of the periurethral area by fecal or vaginal flora, followed by the ascension of these bacteria into the bladder. Women are more susceptible due to anatomical factors such as a shorter urethra and the proximity of the urethra to the rectum. While traditionally, urinary tract infections (UTIs) in men were considered complicated, uncomplicated cystitis can occur in younger, sexually active men without underlying risk factors for complicated UTIs.

Epidemiology of Cystitis

Urinary tract infections are incredibly common, with approximately one-third of women experiencing a UTI by the age of 24 and half by age 32. The annual incidence in women is estimated to be around 12%. Risk factors for uncomplicated cystitis in women include sexual activity, spermicide use, a new sexual partner, a history of UTIs, a family history of UTIs, and being post-menopausal.

Complicated UTIs are associated with a wide range of underlying conditions, leading to variable incidence rates. For example, asymptomatic bacteriuria is more prevalent in women with diabetes compared to non-diabetic women. Other risk factors for complicated UTIs include diabetes, renal transplantation, pregnancy, nephrolithiasis, immunocompromised states, urinary catheters, urinary tract instrumentation, renal insufficiency, and structural or functional abnormalities of the urinary tract. Simple cystitis is less common in men, with an estimated incidence of fewer than 10 cases per 10,000 men under 65 years of age.

Clinical Presentation: Symptoms Overlap and the Need for Differential Diagnosis

Patients with acute cystitis typically present with characteristic urinary symptoms:

  • Dysuria: Painful urination is a hallmark symptom.
  • Urinary Frequency: An increased need to urinate.
  • Urinary Urgency: A sudden, compelling urge to urinate.
  • Suprapubic Pain or Tenderness: Pain in the lower abdomen, above the pubic bone.
  • Hematuria: Blood in the urine may be present.

While these symptoms are suggestive of cystitis, they are not exclusive to this condition. Several other conditions can mimic cystitis, making differential diagnosis critical. For instance, dysuria and urinary frequency can also be symptoms of vaginitis, urethritis, and painful bladder syndrome. The presence of vaginal discharge or irritation alongside dysuria might point towards vaginitis rather than cystitis. Similarly, in men, symptoms of lower UTI can overlap with prostatitis, and additional symptoms like fever, pelvic, or perineal pain may indicate prostatitis rather than simple cystitis.

In older adults and young children, symptoms of cystitis can be atypical and subtle, further emphasizing the importance of considering alternative diagnoses when the presentation is not classic. Relying solely on symptoms like urine cloudiness or foul odor is insufficient for diagnosing cystitis and can lead to misdiagnosis if other conditions are not considered.

Cystitis Differential Diagnosis: Key Considerations

When a patient presents with symptoms suggestive of cystitis, a thorough differential diagnosis is essential. It involves systematically considering and excluding other conditions that can cause similar symptoms. The key conditions to consider in the differential diagnosis of cystitis include:

1. Vaginitis

Vaginitis is an inflammation or infection of the vagina, often caused by bacteria (bacterial vaginosis), yeast (candidiasis), or protozoa (Trichomonas vaginalis).

Differentiating features from cystitis:

  • Vaginal Discharge: A key distinguishing feature of vaginitis. The discharge can vary in color, consistency, and odor depending on the cause. Cystitis typically does not present with vaginal discharge.
  • Dyspareunia: Pain during sexual intercourse is common in vaginitis but not typically associated with cystitis.
  • Pruritus: Vaginal itching is a prominent symptom of vaginitis, especially in yeast infections, and is not a typical symptom of cystitis.
  • Absence of Urinary Urgency and Frequency: While dysuria may be present in vaginitis, urinary urgency and frequency are less prominent compared to cystitis.
  • Pelvic Exam Findings: Pelvic examination in vaginitis reveals vaginal inflammation and discharge, whereas in cystitis, the pelvic exam may be normal or show suprapubic tenderness.

2. Urethritis

Urethritis is an inflammation of the urethra, often caused by sexually transmitted infections (STIs) such as Chlamydia trachomatis or Neisseria gonorrhoeae, but can also be non-infectious.

Differentiating features from cystitis:

  • Pyuria without Bacteriuria: Urinalysis in urethritis may show white blood cells (pyuria) but lack significant bacteria (bacteriuria) on standard urine culture. Cystitis usually presents with both pyuria and bacteriuria.
  • STI Risk Factors: Urethritis is more likely in sexually active individuals, especially those with risk factors for STIs.
  • Gradual Onset of Symptoms: Urethritis symptoms may develop more gradually compared to the often acute onset of cystitis.
  • Urethral Discharge: While less common than vaginal discharge in vaginitis, urethral discharge may be present in urethritis, particularly in men.
  • Absence of Marked Urinary Frequency and Urgency: While dysuria is a key symptom, urinary frequency and urgency might be less pronounced compared to cystitis.

3. Prostatitis

Prostatitis is an inflammation or infection of the prostate gland, primarily affecting men. It can be acute or chronic, bacterial or non-bacterial.

Differentiating features from cystitis:

  • Symptoms in Men: Prostatitis is a condition specific to men, whereas cystitis is common in both sexes but significantly more prevalent in women.
  • Perineal or Pelvic Pain: Prostatitis often presents with pain in the perineum, lower back, or pelvis, which is less typical in uncomplicated cystitis.
  • Ejaculatory Pain: Pain during or after ejaculation is a characteristic symptom of prostatitis.
  • Obstructive Urinary Symptoms: Prostatitis may cause urinary hesitancy, weak stream, or incomplete emptying due to prostate swelling.
  • Systemic Symptoms: Acute bacterial prostatitis can be associated with fever, chills, and malaise, indicating a more systemic infection than typical cystitis.
  • Prostate Exam Findings: A digital rectal exam in acute bacterial prostatitis may reveal a tender, swollen, and boggy prostate. Chronic prostatitis may have less pronounced exam findings.

4. Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)

PBS/IC is a chronic condition characterized by bladder pain, pressure, and urinary urgency and frequency, in the absence of identifiable infection or other clear pathology.

Differentiating features from cystitis:

  • Absence of Infection: Crucially, urinalysis in PBS/IC is negative for bacteria and typically shows no significant pyuria. Cystitis is defined by the presence of infection.
  • Chronic and Persistent Symptoms: PBS/IC is a chronic condition with symptoms lasting for longer durations and often recurring over years, unlike acute cystitis which is typically of shorter duration and responds to antibiotics.
  • Pain Predominant Symptom: Pain, pressure, and discomfort in the bladder and pelvic area are more central to the symptom complex of PBS/IC than in cystitis, where urinary symptoms are often more prominent.
  • Symptom Exacerbation with Bladder Filling: Symptoms in PBS/IC often worsen as the bladder fills and may be relieved by urination.
  • Diagnosis of Exclusion: PBS/IC is diagnosed after excluding other conditions, including infections, making differential diagnosis paramount.

5. Pelvic Inflammatory Disease (PID)

PID is an infection of the female reproductive organs, usually caused by STIs, affecting the uterus, fallopian tubes, and ovaries.

Differentiating features from cystitis:

  • Pelvic and Lower Abdominal Pain: PID is characterized by significant pelvic and lower abdominal pain, often more severe and diffuse than the suprapubic discomfort in cystitis.
  • Cervical Discharge or Tenderness: Pelvic exam in PID may reveal cervical motion tenderness and abnormal cervical discharge.
  • Fever and Systemic Illness: PID is more likely to present with fever, chills, and systemic symptoms compared to uncomplicated cystitis.
  • Upper Genital Tract Involvement: PID involves the uterus, fallopian tubes, and ovaries, whereas cystitis is localized to the bladder.
  • STI Risk Factors: Similar to urethritis, PID is strongly associated with sexual activity and risk factors for STIs.

6. Atrophic Vaginitis

Atrophic vaginitis (genitourinary syndrome of menopause) is a condition that occurs due to decreased estrogen levels, typically in post-menopausal women, leading to thinning and inflammation of the vaginal tissues.

Differentiating features from cystitis:

  • Post-menopausal Women: Atrophic vaginitis is primarily seen in post-menopausal women due to estrogen decline.
  • Vaginal Dryness and Dyspareunia: Vaginal dryness and pain during intercourse are prominent symptoms due to vaginal atrophy.
  • Thin, Watery Vaginal Discharge: Discharge in atrophic vaginitis is typically thin and watery, unlike the purulent discharge in infectious vaginitis.
  • Pale Vaginal Mucosa: On pelvic exam, the vaginal tissues may appear pale and thin due to estrogen deficiency.
  • Urinary Symptoms Secondary to Urethral Atrophy: Dysuria and urinary frequency can occur due to urethral atrophy, but they are often less severe and may be secondary to the vaginal symptoms.

Diagnostic Evaluation and the Role of Differential Diagnosis

The diagnostic approach to suspected cystitis should incorporate the consideration of differential diagnoses. While typical cystitis in young, healthy women with classic symptoms may be diagnosed clinically, laboratory confirmation is generally recommended, especially when differential diagnoses are being considered or symptoms are atypical.

Key diagnostic tools include:

  • Urinalysis: Essential to detect pyuria and nitrites, suggestive of UTI. However, in conditions like urethritis, pyuria may be present without bacteriuria. In PBS/IC, urinalysis is typically normal.
  • Urine Culture: Identifies the causative pathogen and its antibiotic susceptibility, crucial for guiding treatment, particularly in complicated cases or when considering differential diagnoses like prostatitis or recurrent infections. Urine culture is negative in PBS/IC and may be negative in some cases of urethritis if non-infectious or if fastidious organisms are involved.
  • Pelvic Examination: Important in women to assess for vaginitis, urethritis, or PID. Findings such as vaginal discharge, cervical motion tenderness, or vaginal atrophy can point towards alternative diagnoses.
  • Prostate Examination (Digital Rectal Exam): In men presenting with lower urinary tract symptoms, a prostate exam is crucial to evaluate for prostatitis.
  • STI Testing: If urethritis or PID is suspected, testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis is indicated.
  • Cystoscopy and Imaging: In cases of recurrent UTIs, complicated cystitis, or when structural abnormalities are suspected (which might predispose to conditions mimicking cystitis), further investigations like cystoscopy, ultrasound, or CT scans may be necessary to rule out underlying conditions.

The diagnostic process should be guided by the patient’s history, clinical presentation, risk factors, and initial urinalysis findings. When symptoms are not typical for uncomplicated cystitis, or when there is no response to initial antibiotic therapy, a more comprehensive evaluation focusing on differential diagnosis is warranted.

Treatment and Management: Tailoring Therapy Based on Accurate Diagnosis

The treatment of cystitis is primarily with antibiotic therapy. However, accurate differential diagnosis is critical to ensure that treatment is appropriately targeted. For example, antibiotics are ineffective for vaginitis (unless bacterial vaginosis) and PBS/IC. Misdiagnosing vaginitis or PBS/IC as cystitis and prescribing antibiotics can lead to unnecessary antibiotic use, contributing to antibiotic resistance and not addressing the patient’s actual condition.

  • Uncomplicated Cystitis: Typically treated with short-course antibiotics like nitrofurantoin, trimethoprim-sulfamethoxazole (if local resistance is low), or fosfomycin.
  • Complicated Cystitis: Requires longer courses of antibiotics, often broader spectrum, guided by urine culture and susceptibility testing.
  • Vaginitis: Treatment depends on the cause: antifungals for yeast infections, antibiotics for bacterial vaginosis and trichomoniasis.
  • Urethritis (STI-related): Antibiotics effective against Chlamydia and Gonorrhea are used, often empiric pending STI test results.
  • Prostatitis: Prolonged antibiotic courses are needed, often with fluoroquinolones or trimethoprim-sulfamethoxazole due to prostate penetration.
  • PBS/IC: Not treated with antibiotics. Management focuses on symptom relief through lifestyle modifications, bladder training, pain management, and medications like pentosan polysulfate sodium.
  • Atrophic Vaginitis: Treatment involves topical estrogen therapy to restore vaginal tissue health.

Therefore, a correct diagnosis through careful differential diagnosis is not only crucial for effective symptom relief but also for avoiding inappropriate antibiotic use and guiding patients towards the most beneficial and targeted management strategy for their specific condition.

Conclusion

Cystitis is a common condition, but its symptom presentation can overlap with various other urological and gynecological conditions. A thorough approach to cystitis differential diagnosis is paramount for clinicians. By considering conditions such as vaginitis, urethritis, prostatitis, painful bladder syndrome, pelvic inflammatory disease, and atrophic vaginitis, and by utilizing appropriate diagnostic tools, clinicians can accurately differentiate cystitis from its mimics. This precise diagnostic approach ensures that patients receive targeted and effective treatment, avoiding unnecessary antibiotic exposure and improving overall patient outcomes. Understanding the nuances of differential diagnosis in patients presenting with lower urinary tract symptoms is a cornerstone of responsible and effective clinical practice.

References

[Include all references from the original article here, maintaining the same format and links]

1.Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13507. [PubMed: 30793386]
2.Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D. COSUTI: a protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults. Trials. 2019 Feb 07;20(1):106. [PMC free article: PMC6367821] [PubMed: 30732617]
3.Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur). 2010 Apr;5(2):111-5. [PMC free article: PMC3150015] [PubMed: 21977133]
4.Byron JK. Urinary Tract Infection. Vet Clin North Am Small Anim Pract. 2019 Mar;49(2):211-221. [PubMed: 30591189]
5.Karamali M, Shafabakhsh R, Ghanbari Z, Eftekhar T, Asemi Z. Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression. J Cell Physiol. 2019 Aug;234(8):12301-12308. [PubMed: 30609029]
6.Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infect Dis. 2018 Nov;5(11):ofy297. [PMC free article: PMC6284462] [PubMed: 30539040]
7.Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ., EMERGEncy ID Net Study Group. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerg Infect Dis. 2016 Sep;22(9):1594-603. [PMC free article: PMC4994338] [PubMed: 27532362]
8.Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR., VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013 Nov;57(9):1256-65. [PMC free article: PMC3792724] [PubMed: 23926176]
9.Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278. [PubMed: 29539622]
10.Suárez Fernández ML, Ridao Cano N, Álvarez Santamarta L, Gago Fraile M, Blake O, Díaz Corte C. A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients. Diagnostics (Basel). 2021 Aug 12;11(8) [PMC free article: PMC8392421] [PubMed: 34441390]
11.Sabih A, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Complicated Urinary Tract Infections. [PubMed: 28613784]
12.Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol. 1993 May;149(5):1046-8. [PubMed: 8483206]
13.Tyagi P, Moon CH, Janicki J, Kaufman J, Chancellor M, Yoshimura N, Chermansky C. Recent advances in imaging and understanding interstitial cystitis. F1000Res. 2018;7 [PMC free article: PMC6234747] [PubMed: 30473772]
14.Pinto H, Simões M, Borges A. Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2021 Jul 08;10(7) [PMC free article: PMC8300799] [PubMed: 34356749]
15.Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013 Nov 14;369(20):1883-91. [PMC free article: PMC4041367] [PubMed: 24224622]
16.Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002 May 22-29;287(20):2701-10. [PubMed: 12020306]
17.Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009 Jun;57(6):963-70. [PMC free article: PMC2692075] [PubMed: 19490243]
18.Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019 Aug;202(2):282-289. [PubMed: 31042112]
19.Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc. 2014 Feb;15(2):133-9. [PubMed: 24461240]
20.Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract. 2011 May 19;12:36. [PMC free article: PMC3142216] [PubMed: 21592413]
21.Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ. 2019 Feb 27;364:l440. [PMC free article: PMC6391655] [PubMed: 30814052]
22.Kulchavenya EV, Neymark AI, Borisenko DV, Kapsargin FP. [Acute uncomplicated cysititis: do we follow the guidelines?]. Urologiia. 2018 Dec;(6):66-69. [PubMed: 30742380]
23.Phamnguyen TJ, Murphy G, Hashem F. Single centre observational study on antibiotic prescribing adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infection. Infect Dis Health. 2019 May;24(2):75-81. [PubMed: 30598405]
24.Bono MJ, Leslie SW, Reygaert WC, Doerr C. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections (Nursing) [PubMed: 33760460]
25.Bono MJ, Leslie SW, Reygaert WC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections. [PubMed: 29261874]
26.Swamy S, Kupelian AS, Khasriya R, Dharmasena D, Toteva H, Dehpour T, Collins L, Rohn JL, Malone-Lee J. Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis. Int Urogynecol J. 2019 Mar;30(3):409-414. [PMC free article: PMC6394536] [PubMed: 30564872]
27.May M, Schostak M, Lebentrau S., MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2019 Feb;30(2):335-336. [PubMed: 30564871]
28.Bellazreg F, Abid M, Lasfar NB, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study. Pan Afr Med J. 2019;33:131. [PMC free article: PMC6754830] [PubMed: 31558930]
29.Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004 Apr 15;38(8):1150-8. [PubMed: 15095222]
30.Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians. Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-827. [PubMed: 33819054]
31.McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc. 2011 Jun;86(6):480-8. [PMC free article: PMC3104907] [PubMed: 21576512]
32.Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64. [PubMed: 26066581]
33.Sheele JM, Libertin CR, Fink I, Jensen T, Dasalla N, Lyon TD. Alkaline Urine in the Emergency Department Predicts Nitrofurantoin Resistance. J Emerg Med. 2022 Mar;62(3):368-377. [PubMed: 35000812]
34.Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999 Mar;43 Suppl A:67-75. [PubMed: 10225575]
35.Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, Poulakou G, Hatzipapas A, Koratzanis G. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother. 2003 Mar;47(3):897-900. [PMC free article: PMC149311] [PubMed: 12604518]
36.Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999 Oct;29(4):745-58. [PubMed: 10589881]
37.Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis. 1988 Jun;157(6):1239-42. [PubMed: 3259613]
38.Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999 Nov;21(11):1864-72. [PubMed: 10890258]
39.Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321-47. [PMC free article: PMC4786888] [PubMed: 26960938]
40.Schulz GS, Schütz F, Spielmann FVJ, da Ros LU, de Almeida JS, Ramos JGL. Single-dose antibiotic therapy for urinary infections during pregnancy: A systematic review and meta-analysis of randomized clinical trials. Int J Gynaecol Obstet. 2022 Oct;159(1):56-64. [PubMed: 34995367]
41.Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020 Jul 01;75(7):1993-1997. [PubMed: 32303061]
42.Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. Open Forum Infect Dis. 2022 Jan;9(1):ofab620. [PMC free article: PMC8754378] [PubMed: 35036466]
43.Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [PubMed: 14527775]
44.Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, Bru JP, Mckinnon C, O’Doherty B, Spiegel W, Van Balen FA, Menday P. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis. 2002;34(7):487-92. [PubMed: 12195873]
45.Nace DA, Perera SK, Hanlon JT, Saracco S, Anderson G, Schweon SJ, Klein-Fedyshin M, Wessel CB, Mulligan M, Drinka PJ, Crnich CJ. The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents. J Am Med Dir Assoc. 2018 Sep;19(9):765-769.e3. [PMC free article: PMC8043108] [PubMed: 30037743]
46.Cox L, He C, Bevins J, Clemens JQ, Stoffel JT, Cameron AP. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J. 2017 Sep;11(9):E350-E354. [PMC free article: PMC5798439] [PubMed: 29382457]
47.Lala V, Leslie SW, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Acute Cystitis. [PubMed: 29083726]
48.Ziadeh T, Chebel R, Labaki C, Saliba G, Helou EE. Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review. Urologia. 2022 May;89(2):261-267. [PubMed: 34612750]
49.Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014 May;12(5):549-54. [PubMed: 24689705]
50.Kevorkian CG, Merritt JL, Ilstrup DM. Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder. Mayo Clin Proc. 1984 Aug;59(8):523-9. [PubMed: 6379319]
51.Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. [PubMed: 23633128]
52.Kyriakides R, Jones P, Somani BK. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2021 Sep;7(5):1166-1169. [PubMed: 32972899]
53.Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Aug;223(2):265.e1-265.e13. [PMC free article: PMC7395894] [PubMed: 32497610]
54.De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics (Basel). 2021 Apr 01;10(4) [PMC free article: PMC8066587] [PubMed: 33915821]
55.Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007 Jan;86(1):47-53. [PubMed: 17220755]
56.Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007 Jul;100(1):17-20. [PubMed: 17506870]
57.Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infect Dis Ther. 2022 Dec;11(6):2297-2310. [PMC free article: PMC9589544] [PubMed: 36271314]
58.Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. [PMC free article: PMC9664842] [PubMed: 36255258]
59.Tiffany C, Dumont EF, Hossain M, Srinivasan M, Swift B. Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects. Clin Transl Sci. 2022 Sep;15(9):2251-2264. [PMC free article: PMC9468557] [PubMed: 35769034]
60.Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother. 2016 Jan 04;60(3):1918-23. [PMC free article: PMC4776004] [PubMed: 26729499]
61.Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol. 1997 Jun;157(6):2049-52. [PubMed: 9146577]
62.Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003 Sep;170(3):867-9. [PubMed: 12913718]
63.Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007 Apr;177(4):1349-53; quiz 1591. [PubMed: 17382730]
64.Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D’Antonio E, Krejci KG, Shore N, Peterson J, Lukes AS, Starks CM. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Hum Vaccin Immunother. 2021 May 04;17(5):1262-1270. [PMC free article: PMC8078672] [PubMed: 33325785]
65.Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997 Apr 25;276(5312):607-11. [PubMed: 9110982]
66.Forsyth VS, Himpsl SD, Smith SN, Sarkissian CA, Mike LA, Stocki JA, Sintsova A, Alteri CJ, Mobley HLT. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection. mBio. 2020 Apr 28;11(2) [PMC free article: PMC7188996] [PubMed: 32345645]
67.Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013 Dec;190(6):1981-9. [PubMed: 23867306]
68.Wang Q, Sun M, Ma C, Lv H, Lu P, Wang Q, Liu G, Hu Z, Gao Y. Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review. Medicine (Baltimore). 2018 Nov;97(45):e11272. [PMC free article: PMC6250534] [PubMed: 30407278]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *